Clinical trial · Interventional
Evidence-Based Practice for the Management of Musculoskeletal Symptoms in Breast Cancer Patients Undergoing Endocrine Therapy: A Multicultural Perspective
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
The purpose of this implementation study is to evaluate the application of an evidence-based practice (EBP) program for managing musculoskeletal symptoms in breast cancer patients receiving endocrine therapy, from a multicultural perspective. The main questions it aims to answer are: Is the culturally adapted EBP program feasible and acceptable to implement in real-world clinical settings? Does the implementation of this program effectively reduce patients' musculoskeletal symptoms and improve their quality of life? Researchers will compare the group receiving the cross-culturally adapted evidence-based management with a group receiving standard routine care. During the study: Healthcare providers will implement the culturally tailored symptom management program. Participants will receive targeted health education and nursing guidance based on their cultural context. Researchers will collect data on how well the program is adopted (implementation outcomes), as well as evaluate changes in patients' joint symptoms and overall well-being at designated follow-up times (clinical outcomes).
Conditions
Conditions (2)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Aromatase Inhibitor-Associated Musculoskeletal Symptoms (AIMSS) | — | UNRESOLVED | — |
| Breast Neoplasms | Breast Neoplasm | ONTOLOGY_EXACT | 0.98 |
Interventions
Interventions (2)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Culturally Adapted EBP Program | Behavioral | — | UNRESOLVED |
| Standard Routine Care | Other | — | UNRESOLVED |
Design
Arms and outcomes
Arms (2)
- type
- EXPERIMENTAL
- label
- Evidence-Based Practice (EBP) Group
- description
- Participants receive a culturally adapted evidence-based symptom management program, including targeted health education and nursing guidance.
- interventionNames
- Behavioral: Culturally Adapted EBP Program
- type
- ACTIVE_COMPARATOR
- label
- Routine Care Group
- description
- Participants receive standard routine clinical care without the additional evidence-based management program.
- interventionNames
- Other: Standard Routine Care
Primary outcomes (2)
- measure
- Change in Joint Function Assessed by the WOMAC Index
- timeFrame
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * Pathologically diagnosed Hormone Receptor Positive (HR+) primary breast cancer * Aged 18 years or older * Currently receiving Aromatase Inhibitors (AIs) endocrine therapy for at least 6 months * Self-reported Aromatase Inhibitor-induced Musculoskeletal Symptoms (AIMSS) * Possess basic communication skills, able to understand the research content, and voluntarily provide written informed consent * For the qualitative implementation evaluation, practitioners must be substantially involved in the clinical implementation of the AIMSS management program (e.g., patient recruitment, intervention delivery, digital tool guidance, or follow-up) * For the qualitative implementation evaluation, practitioners must provide informed consent for recorded interviews Exclusion Criteria: * History of bone fracture or related orthopedic surgery within the past 6 months * Previously diagnosed with inflammatory joint diseases (e.g., rheumatoid arthritis, ankylosing spondylitis) * Received other treatments for AIMSS not included in this study protocol within the past 1 month * Diagnosed with metastatic breast cancer or other primary malignant tumors * Concurrent serious dysfunction of vital organs (heart, brain, kidney, etc.) or uncontrolled infectious diseases * Presence of severe mental illness or cognitive impairment that prevents cooperation with the longitudinal study process
References
Publications (0)
Data not yet available